FDA Approved: XULTOPHY 100/3.6 — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for Xultophy 100/3.6, a fixed-ratio combination of insulin degludec and liraglutide, by Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• XULTOPHY 100/3.6 (insulin degludec and liraglutide)

Snippet

SUPPL AP for XULTOPHY 100/3.6 (INSULIN DEGLUDEC AND LIRAGLUTIDE)